We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.63%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.76B
AUM Growth
+$122M
Cap. Flow
-$172M
Cap. Flow %
-6.22%
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5

Top Buys

Rank Stock Value
1
ZTS icon
Zoetis
ZTS
+$17M
2
JNJ icon
Johnson & Johnson
JNJ
+$13.8M
3
NVO
Novo Nordisk
NVO
+$8.1M
4
ELV icon
Elevance Health
ELV
+$7.92M
5
TMO icon
Thermo Fisher Scientific
TMO
+$6.37M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$42.7M
2
PFE icon
Pfizer
PFE
+$40.8M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$30.9M
4
UNH icon
UnitedHealth
UNH
+$21M
5
LLY icon
Eli Lilly
LLY
+$17.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.4%
2 Real Estate 2.75%
3 Miscellaneous 1.24%
4 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CAH icon
201
Cardinal Health
CAH
$54.1B
$340K 0.01%
6,300
– –
EIDX
202
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$278K 0.01%
+27,900
New +$459K
TBPH icon
203
Theravance Biopharma
TBPH
$884M
$264K 0.01%
8,083
– –
NCNA
204
NuCana
NCNA
$5.45M
$245K 0.01%
2
– –
YARW
205
Yarrow Bioscience
YARW
$67.8M
$244K 0.01%
+7
New +$216K
XENT
206
DELISTED
Intersect ENT, Inc
XENT
$240K 0.01%
+8,356
New +$251K
QHC
207
DELISTED
Quorum Health Corporation
QHC
$139K 0.01%
23,725
– –
JNCE
208
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$66K ﹤0.01%
10,127
– –
CLDX icon
209
Celldex Therapeutics
CLDX
$3.03B
$48K ﹤0.01%
7,053
– –
ASRT
210
DELISTED
Assertio
ASRT
$6K ﹤0.01%
17
-1,033
-98% -$451K
TXMD icon
211
TherapeuticsMD
TXMD
$25M
– –
-4,688
Closed -$1.46M
XENE icon
212
Xenon Pharmaceuticals
XENE
$5.51B
– –
-163,819
Closed -$1.51M
NSTG
213
DELISTED
NanoString Technologies, Inc.
NSTG
– –
-74,250
Closed -$1.02M
RARX
214
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-219,952
Closed -$2.19M
WELL.PRI
215
DELISTED
Welltower Inc.
WELL.PRI
– –
-200,000
Closed -$11.9M
5 6 7 8
9

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Tekla Capital Management held 217 positions worth $2.76B, up 4.6% from $2.64B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

Tekla Capital Management withdrew a net $172M in Q3 2018, closing 5 positions and reducing 47 holdings. Its most notable exit was Welltower Inc., an estimated $11.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Real Estate and Miscellaneous.

Against the trend, Tekla Capital Management opened a new position in Quest Diagnostics worth $4.21M.

  • Tekla Capital Management's largest Q3 2018 buy was Quest Diagnostics: 39,000 shares worth $4.21M.
  • Tekla Capital Management added most to Zoetis in Q3 2018, an estimated $17M increase.
  • Tekla Capital Management's biggest Q3 2018 reduction was Merck, cutting an estimated $42.7M.
  • Tekla Capital Management fully exited Welltower Inc. in Q3 2018, selling an estimated $11.9M.
  • Tekla Capital Management's ten largest holdings make up 39% of its $2.76B portfolio in Q3 2018.
  • Tekla Capital Management opened 37 new positions and closed 5 in Q3 2018.
  • Tekla Capital Management's portfolio value rose 4.6% quarter-over-quarter to $2.76B.

Based on Tekla Capital Management's 13F filing for Q3 2018, filed 13 Nov 2018.